Which company developed bimekizumab?

Bimekizumab (Bimekizumab) is a humanized dual-target biological agent developed by the Belgian pharmaceutical company UCB. UCB is a multinational pharmaceutical company that has long been focused on the treatment of immune diseases and neurological diseases. Its product pipeline includes a number of innovative drugs targeting complex immune pathways. As one of its key projects, bichizumab has attracted global attention from the early stages of research and development for its characteristic of "simultaneously inhibiting IL-17A and IL-17F". Compared with traditional treatment strategies that single-target IL-17A, UCB hopes to enable patients with plaque psoriasis, psoriatic arthritis and other diseases to achieve deeper and more lasting improvements in skin and systemic inflammation through more comprehensive control of inflammatory pathways.

The development process of bicizumab stems fromUCB’s years of research accumulation in the field of immunology. The IL-17 inflammatory pathway is considered an important signaling axis in psoriasis and related diseases, and blocking IL-17A and IL-17F at the same time can more broadly inhibit the abnormal activation of related inflammatory factors, chemokines, and keratinocytes. On this basis, UCB created the IgG1/κ monoclonal antibody molecule Bicizumab , which has stronger target binding ability and better tissue penetration, thus showing better long-lasting efficacy in multiple overseas studies.

As bichizumab has been successively approved overseas, UCB has also simultaneously promoted its clinical development in more indications, including immune-related diseases such as psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis. The company's continued deployment in the field of immunology has made bichizumab its strategic product and allowed it to occupy a more distinct position in the global IL-17 pathway inhibitor market.

At present, bichizumab has been approved for moderate to severe plaque psoriasis in many countries such as Europe, the United States, and Japan, and its commercialization process has gradually matured. Due toUCB’s long-term experience in production quality and supply chain management, the drug has strong supply stability around the world.

Reference materials:https://www.drugs.com/bimekizumab.html